Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Reddy’s Launches Generic Versions Of GSK’s Imitrex; Ranbaxy May Have To Wait

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - One more blockbuster drug will be available to U.S. citizens at a fraction of its brand price as India's Dr Reddy's announced the launch of generic versions of GlaxoSmithKline's anti-migraine drug Imitrex (sumatriptan)

You may also be interested in...



Ranbaxy Gets U.S. FDA Nod For Imitrex After Four Months Of Waiting

MUMBAI - Four months after the U.S. FDA imposed an import alert on 33 products manufactured by Ranbaxy, the company received a much needed shot in the arm after the drug regulator approved launch of its generic versions of GlaxoSmithKline's migraine drug Imitrex (sumatriptan) 100 mg, which has sales of over $1.1 billion in the U.S. alone

Ranbaxy Gets U.S. FDA Nod For Imitrex After Four Months Of Waiting

MUMBAI - Four months after the U.S. FDA imposed an import alert on 33 products manufactured by Ranbaxy, the company received a much needed shot in the arm after the drug regulator approved launch of its generic versions of GlaxoSmithKline's migraine drug Imitrex (sumatriptan) 100 mg, which has sales of over $1.1 billion in the U.S. alone

Ranbaxy May Face Third-Party Oversight Of Ganciclovir Manufacturing

Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from U.S. FDA's Import Alert

Related Content

UsernamePublicRestriction

Register

ID1132281

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel